An Early Phase 1 interventional study of D-Cycloserine and Placebo in Social Anxiety Disorder, sponsored by Jasper A. Smits. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Jasper A. Smits · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.
Among the 187 studies in Phobia, Social with a site in United States, this one is the 46th largest by enrollment of the 178 interventional ones that give a count, is one of 11 that started in 2014, is one of 10 in phase 1, and was the 70th registered.
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
Browse Phobia, Social studies →23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:
Jason Careri · Sites in United States
Ages 18–65
Andrew Wiese · Sites in United States
Ages 7–17
Newleos Therapeutics, Inc. · Sites in United States
Ages 18–65
Bradley Hospital · Sites in United States
Ages 5–18
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 34 · Phase 3 21 · Phase 4 18
First in 1998; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 76 across 339 interventional studies indexed under Phobia, Social.
Median enrollment 64 across the 178 interventional studies, 184 across the 8 observational. Of the 146 that completed or were terminated, 59 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 187 have an industry lead sponsor. The 10 most frequent:
Jasper A. Smits is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Jasper A. Smits has 3 studies filed under Phobia, Social — fewer than ten, so there is no comparison to draw.
13 of the studies in Phobia, Social with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221578Phase 3Vanda PharmaceuticalsStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | 2026-12 |
| NCT04663724New York State Psychiatric InstituteComputer - Based Treatment for Social Anxiety Disorder | 2026-11-30 |
| NCT07589621Florida State UniversitySafety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
| NCT07028216Georgetown UniversityMindful Self-compassion for Anxiety and Depression: Impact of Delivery Method | 2026-12-17 |
Add all 13 to your calendar (.ics) → With an account.
Among the 187 studies in Phobia, Social with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison to placebo (a pill containing no medication) for improving the effectiveness of cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. In addition, the study will examine whether the effectiveness of d-cycloserine depends on the timing of the pill administration (i.e., 1- hour before the session or immediately after the session) as well as the success of the CBT therapy sessions. The investigators hypothesize that the tailored post-session DCS administration condition will outperform the other conditions (pre-session DCS, placebo, and non-tailored post-session DCS). This will be evidenced by short- and long-term improvements in social anxiety severity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
Drug: D-Cycloserine · Drug: Placebo · Behavioral: Cognitive Behavioral Therapy
Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
Drug: D-Cycloserine · Drug: Placebo · Behavioral: Cognitive Behavioral Therapy
Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
Drug: Placebo · Behavioral: Cognitive Behavioral Therapy
Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
Drug: D-Cycloserine · Drug: Placebo · Behavioral: Cognitive Behavioral Therapy
D-cycloserine is a medication thought to be associated with fear extinction.
Also known as: D-cycloserine, DCS
Sugar pill
This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
Also known as: CBT
Social Anxiety Symptom Severity
The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form). "The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity. The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.
Time frame: Assessments took place at multiple time points from baseline to 3-month follow-up. The three-month is reported
| Milestone | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS |
|---|---|---|---|---|
| Started | 40 | 38 | 38 | 36 |
| Completed | 33 | 33 | 30 | 27 |
| Not completed | 7 | 5 | 8 | 9 |
The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form). "The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity. The LSAS is a 24-item scale that measures fear and avoidance in social and performance situations within the last week, using 0 (no fear/never avoids) to 3 (severe fear/usually avoids) scale. LSAS scores range from 0-144 with higher scores indicated worse outcomes. The SPD-S is the Clinical Global Impression Scale27 adapted for SAD, which instructs evaluators to use a 7-point scale (1=normal, not at all ill; 7=among the most extremely ill patients) to index the severity of social anxiety.
| score on a scale | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS |
|---|---|---|---|---|
| Social Anxiety Symptom Severity | -.46 ± .13 | -.90 ± .13 | -.39 ± .14 | -.88 ± .14 |
Collected over Data for adverse events was collected at each assessment point over the course of the study (e.g., in-person screening, baseline appointment, sessions 1-5, and the 1-week, 1-month, and 3-month follow-ups).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tailored Post-Session DCS | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Pre-Session DCS | 0/38 (0%) | 0/38 (0%) | 0/38 (0%) |
| Placebo | 0/38 (0%) | 1/38 (2.6%) | 0/38 (0%) |
| Non-Tailored Post-Session DCS | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Event | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS |
|---|---|---|---|---|
| Serious Adverse EventPsychiatric disorders | 0/40 | 0/38 | 1/38 | 0/36 |
| Age, Categorical(Participants) | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 38 | 38 | 36 | 152 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS | Total |
|---|---|---|---|---|---|
| Mean | 30.78 ± 9.88 | 29.73 ± 10.42 | 28.76 ± 11.81 | 27.54 ± 8.29 | 29.20 ± 10.1 |
| Sex: Female, Male(Participants) | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS | Total |
|---|---|---|---|---|---|
| Female | 24 | 22 | 18 | 21 | 85 |
| Male | 16 | 16 | 20 | 15 | 67 |
| Ethnicity (NIH/OMB)(Participants) | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 10 | 9 | 30 |
| Not Hispanic or Latino | 33 | 32 | 26 | 25 | 116 |
| Unknown or Not Reported | 2 | 0 | 2 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 7 | 8 | 13 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 5 | 4 | 3 | 20 |
| White | 25 | 23 | 24 | 18 | 90 |
| More than one race | 0 | 1 | 2 | 2 | 5 |
| Unknown or Not Reported | 1 | 2 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Tailored Post-Session DCS | Pre-Session DCS | Placebo | Non-Tailored Post-Session DCS | Total |
|---|---|---|---|---|---|
| United States | 40 | 38 | 38 | 36 | 152 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in Jul 2018, 51 months.
Results were first posted in Jun 2020, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cycloserine
Jasper A. Smits